Summary : Peter Pitts, a former FDA associate commissioner and president of the Center for Medicine in the Public Interest, discusses the…
news
-
-
Summary : Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the…
-
RegulatoryU.S FDA
GC Pharma Receives Complete Response Letter From the U.S. FDA For ‘ALYGLO’
by adminby adminSummary : GC Pharma (KRX:006280) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug…
-
Pharma Science & Research
Autoimmune diseases: discovery of central building block in immune cells
by adminby adminAutoimmune diseases are triggered when the immune system malfunctions and attacks the body’s own structures. Although there is not, as yet, any…
-
CompaniesGlobal MarketNovartis
Syncona announces sale of portfolio company to Novartis
by adminby adminSynopsis : Syncona – a company focused on founding, building and funding global leaders in life science – has announced the sale…
-
Summary : The U.S. Food and Drug Administration has accepted Mirati Therapeutics’ New Drug Application (NDA) for its candidate drug for non-small cell lung cancer (NSCLC). The…
-
Global Market
Western Potash Holdings Corp. and Vantage Chance Limited Enter Into Subscription Agreement
by adminby adminSummary : Western Resources Corp. is pleased to announce that it has signed a subscription agreement (the “Subscription Agreement”) today with Vantage…
-
Global MarketPharma Science & Research
Lilly, Roche Push Back Against CMS Draft Guidance on Aduhelm
by adminby adminSummary The U.S. Centers for Medicare & Medicaid Services (CMS) just completed the open comment period for their draft national coverage decision…
-
-
BiogenGlobal Market
Biogen Officially Weighs in On Medicare Draft Guidance for Aduhelm
by adminby adminSummary – In mid-January, the Centers for Medicare & Medicaid Services (CMS) issued a draft national coverage decision for Biogen’s Alzheimer’s drug…